Company Profile
CelLBxHealth plc, a medical diagnostic company develops cancer diagnostics products globally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis
Parsortix PR1 system captures and harvests circulating tumour cells from blood Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells
CellKeep Slide, a CTC harvesting technology. Additionally, it offers laboratory services, including CTC enrichment and liquid biopsy analysis services. Its portfolio also includes Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, DNA damage response, Portrait PD-L1, evaluates CTCs, and custom CTC assays.
CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel.
It also has a research collaboration with The Royal Marsden NHS Foundation Trust. Founded in 1994 and based in Guildford, the United Kingdom, CelLBxHealth was formerly known as ANGLE plc before rebranding in October 2025.